Haisco Pharmaceutical: Profits up, new dividend policy and equity offer

Haisco Pharmaceutical Group (SZSE:002653) reported a strong 2024, with annual revenue climbing 10.92% to CNY3.72 billion. Net profit attributable to shareholders surged 34% to CNY395 million, driven by key products like 思舒宁® (an anesthetic), where sales increased by 45.60%. The company's board has proposed a cash dividend of CNY0.135 per share, totaling CNY151.18 million, subject to shareholder approval. This brings the total 2024 dividend payout to CNY463.92 million, representing 117.31% of profits attributable to shareholders. The company forecasts continued strong growth in 2025, targeting a 15% increase in revenue via pipeline development and market expansion.